// App-Quantinova.ai

107 : SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic,castrate-refractory prostate cancer (mCRPC)—A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group.

Researchers

Presenter

  • Robert J. Jones

Principal Investigators

  • Johann S. De Bono

  • Christy Ralph

  • Tony Elliott

  • Angus Robinson

  • Charlotte Westbury

  • Alison Jane Birtle

  • John Nicholas Staffurth

  • Andrew Protheroe

  • Balaji Venugopal

  • Fiona Thomson

  • Chantevy Pou

  • Karen Morris

  • Jonathan Tugwood

  • Laura Divers

  • Carol Hopkins

  • Elaine McCartney

  • Caroline Kelly

  • Simon J. Crabb

Medical Centers

  • Institute of Cancer Sciences, Glasgow, United Kingdom

  • University Hospitals Bristol NHS Foundation Trust, Wells Somerset, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • St. James`s Institute of Oncology and University of Leeds, Leeds, United Kingdom.

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Brighton and Sussex University Hospitals NHS Trust, Sussex Cancer Centre, Brighton, United Kingdom

  • Mount Vernon Cancer Centre, Northwood, United Kingdom

  • Rosemere Cancer Centre, Royal Preston Hospital, Preston, United Kingdom

  • Velindre Hospital, Cardiff University, Cardiff, United Kingdom

  • Churchill Hospital, Oxford, United Kingdom

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • University of Glasgow, Glasgow, United Kingdom

  • Cancer Research UK Manchester Institute, Manchester, United Kingdom

  • The University of Manchester, Alderley Park, United Kingdom

  • Cancer Research UK Glasgow Clinical Trials Unit, Glasgow, United Kingdom

  • Southampton Clinical Trials Unit,University of Southampton, Southampton, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • saracatinib

  • Docetaxel

  • AZD-0530

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Drug-Drug Interaction

  • Open Label

  • Dose Escalation

Phase

  • II

Study Id's

  • ISRCTN22566729

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved